MAXALT SUMMARY
MAXALT contains rizatriptan benzoate, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist.
MAXALT® and MAXALT-MLT® are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.
Limitations of Use
- MAXALT should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with MAXALT, the diagnosis of migraine should be reconsidered before MAXALT is administered to treat any subsequent attacks.
- MAXALT is not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4) ].
- MAXALT is not indicated for the prevention of migraine attacks.
- Safety and effectiveness of MAXALT have not been established for cluster headache.
|
|
NEWS HIGHLIGHTSMedia Articles Related to Maxalt (Rizatriptan)
Pictures of Famous People Coping With Migraines
Source: MedicineNet Headache Specialty [2017.09.08]
Title: Pictures of Famous People Coping With Migraines
Category: Slideshows
Created: 11/5/2012 12:00:00 AM
Last Editorial Review: 9/8/2017 12:00:00 AM
Many Migraine Sufferers Given Unecessary Opioids, Study Finds
Source: MedicineNet Headache Specialty [2017.08.28]
Title: Many Migraine Sufferers Given Unecessary Opioids, Study Finds
Category: Health News
Created: 8/25/2017 12:00:00 AM
Last Editorial Review: 8/28/2017 12:00:00 AM
Migraine vs. Headache: Differences and Similarities
Source: MedicineNet Analgesics, Antipyretics Specialty [2017.06.26]
Title: Migraine vs. Headache: Differences and Similarities
Category: Diseases and Conditions
Created: 6/21/2017 12:00:00 AM
Last Editorial Review: 6/26/2017 12:00:00 AM
Migraine
Source: MedicineNet amitriptyline Specialty [2017.05.22]
Title: Migraine
Category: Symptoms and Signs
Created: 2/27/2015 12:00:00 AM
Last Editorial Review: 5/22/2017 12:00:00 AM
Migraine Headache
Source: MedicineNet Antiphospholipid Syndrome Specialty [2017.03.13]
Title: Migraine Headache
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 3/13/2017 12:00:00 AM
Published Studies Related to Maxalt (Rizatriptan)
Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. [2011.05]
OBJECTIVE: The study was carried out to assess the efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treating acute migraine in patients who are non-responders to sumatriptan. BACKGROUND: Many migraineurs report dissatisfaction with sumatriptan efficacy. It is unclear whether sumatriptan 100 mg non-responders will respond to other triptans... CONCLUSION: Rizatriptan 10-mg ODT was superior to placebo at providing two-hour pain relief and two-hour pain freedom in the treatment of acute migraine in those who do not respond to sumatriptan 100 mg. Rizatriptan was generally well tolerated in this population.
A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. [2011.04]
The objective of this study was to assess patient satisfaction with acute treatment of migraine with frovatriptan or rizatriptan by preference questionnaire. 148 subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack per month in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or rizatriptan 10 mg treating 1-3 attacks...
Rizatriptan reduces vestibular-induced motion sickness in migraineurs. [2011.02]
A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation. In this double-blind, randomized, placebo-controlled study we measured motion sickness in response to a complex vestibular stimulus following pretreatment with either rizatriptan or a placebo...
Efficacy of frovatriptan in the acute treatment of menstrually related migraine:
analysis of a double-blind, randomized, cross-over, multicenter, Italian,
comparative study versus rizatriptan. [2011]
The objectives of this study are to assess the efficacy and safety of
frovatriptan, and rizatriptan in the subgroup of women with menstrually related
migraine of a multicenter, randomized, double blind, cross-over study. Each
patient received frovatriptan 2.5 mg or rizatriptan 10 mg in a randomized
sequence: after treating 3 episodes of migraine in not more than 3 months with
the first treatment, the patient had to switch to the other treatment...
A pilot study of rizatriptan and visually-induced motion sickness in migraineurs. [2009.08.06]
CONCLUSIONS: These pilot data suggest that rizatriptan does not consistently reduce visually-induced motion sickness in migraineurs. Rizatriptan may diminish motion sickness potentiation by cranial pain.
Clinical Trials Related to Maxalt (Rizatriptan)
Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1) [Completed]
A study to assess the safety, tolerability, and single dose pharmacokinetics of a marketed
drug in pediatric subjects with migraines.
After completion of a portion of the study (Panels A and B), a regulatory agency issued an
amended request that the 12-17 year old age group studied should include a similar number of
male and female subjects. Therefore, the study was amended to add an additional panel of
subjects (Panel C) to ensure gender balance specifically in this age group.
Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops [Withdrawn]
Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache [Completed]
The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with
caffeine for treating acute attacks of migraine.
Each subject will have 3 months to treat 3 acute migraine headache attacks. Each subject
will be dispensed one box containing 3 packets of study medication labeled for Headache #1,
Headache #2, or Headache #3. Each packet wil contain either Maxalt 10mg MLT or a Maxalt
placebo (sugar pill), and a capsule containing either caffeine 75mg or a capsule containing
placebo (sugar).
One headache will be treated with a combination of Maxalt 10mg MLT and caffeine.
Another headache will be treated with a combination of Maxalt 10mg MLT and a capsule
containing placebo.
A third headache will be treated with just placebo.
Neither the subject, the study coordinator, or your study doctor will know in which order
you will receive the three different treatments. This information is available in case of
emergency.
Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029) [Completed]
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7) [Completed]
Reports of Suspected Maxalt (Rizatriptan) Side Effects
Drug Ineffective (14),
Migraine (10),
Chest Pain (8),
Tremor (8),
Chest Discomfort (7),
Vomiting (7),
Depression (6),
Muscle Twitching (5),
Disability (5),
Blood Creatine Phosphokinase Increased (4), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 10 ratings/reviews, Maxalt has an overall score of 9.40. The effectiveness score is 9.60 and the side effect score is 8.20. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
| | Maxalt review by 47 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | Migraines |
| Dosage & duration: | | 10 mg taken as needed for the period of Ongoing |
| Other conditions: | | None |
| Other drugs taken: | | Birth control | | |
Reported Results |
| Benefits: | | Normally takes away a headache with an hour when absolutely nothing else will work. |
| Side effects: | | Sometimes will give a feeling of tightness in the chest and some drowsiness. If taken too often can cause rebound headaches. |
| Comments: | | You take one Maxalt at the onset of a migraine. It can be repeated after two hours. |
|
| | Maxalt review by 38 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Considerably Effective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | Migraine |
| Dosage & duration: | | 10mg taken 2-6x/year for the period of 1 year |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | Decreased headache pain from 10/10 to 0/10 within a few hours. Took at least 30 minutes to feel pain start to decrease, then causes fatigue. I like the fact that it disintegrates sublingually, because vomiting is often associated with my headaches and I am never sure how much medication is retained afterward if I have taken a tablet. |
| Side effects: | | It always puts me to sleep for an hour or two. After waking, I sometimes feel a little shakey, but the pain is gone. I wouldn't take this med if I were out of the house due to the grogginess. |
| Comments: | | Treatment for migraine when otc's, or prescription level ibuprophen (800 mg) are not effective. Used for moderate migraine if it lasts a few days, or when pain reaches 8 to 10/10. |
|
| | Maxalt review by 38 year old female patient | | | Rating |
| Overall rating: | | |
| Effectiveness: | | Considerably Effective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | Migraine |
| Dosage & duration: | | 10mg taken monthly for the period of ongoing |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | The drug melts on the tongue so there is no need for water and is great when you need to take a tablet in the car etc. It is effective as soon as the effects of a migraine appear and I would reccommend it to anyone who suffers. |
| Side effects: | | I sometimes feel nausea (May also be due to migraine itself). I get sonstipated |
| Comments: | | One tablet is taken whne required and a second one can be taken after two hours no more than 2 to be taken in 24 hours |
|
|
|
Page last updated: 2017-09-08
|
